Yoko Ino (209751)

No ORCID on file · 3 papers in corpus
2016
Secretome-Based Identification of TFPI2, A Novel Serum\nBiomarker for Detection of Ovarian Clear Cell Adenocarcinoma
·doi:10.1021/pr400282j.s002

Of\nall of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma\n(CCA) has the worst clinical prognosis. Furthermore, the conventional\nEOC biomarker CA125 is more often negative in CCA than in other subtypes\nof EOC. This study …

2016
Secretome-Based Identification of TFPI2, A Novel Serum\nBiomarker for Detection of Ovarian Clear Cell Adenocarcinoma
·doi:10.1021/pr400282j.s003

Of\nall of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma\n(CCA) has the worst clinical prognosis. Furthermore, the conventional\nEOC biomarker CA125 is more often negative in CCA than in other subtypes\nof EOC. This study …

2016
Secretome-Based Identification of TFPI2, A Novel Serum\nBiomarker for Detection of Ovarian Clear Cell Adenocarcinoma
·doi:10.1021/pr400282j.s001

Of\nall of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma\n(CCA) has the worst clinical prognosis. Furthermore, the conventional\nEOC biomarker CA125 is more often negative in CCA than in other subtypes\nof EOC. This study …